Future Directions in the Treatment of Osteosarcoma.
Loading...
Embargo End Date
ICR Authors
Authors
Smrke, A
Anderson, PM
Gulia, A
Gennatas, S
Huang, PH
Jones, RL
Anderson, PM
Gulia, A
Gennatas, S
Huang, PH
Jones, RL
Document Type
Journal Article
Date
2021-01-15
Date Accepted
2021-01-13
Abstract
Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd-3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate-doxorubicin-cisplatin (MAP) chemotherapy schedule is strongly predictive of outcome. Outcomes for patients with osteosarcoma have not significantly changed for over thirty years. There is a need for more effective treatment for patients with high risk features but also reduced treatment-related toxicity for all patients. Predictive biomarkers are needed to help inform clinicians to de-escalate or add therapy, including immune therapies, and to contribute to future clinical trial designs. Here, we review a variety of approaches to improve outcomes and quality of life for patients with osteosarcoma with a focus on incorporating toxicity reduction, immune therapy and molecular analysis to provide the most effective and least toxic osteosarcoma therapy.
Citation
Cells, 2021, 10 (1)
Source Title
Publisher
MDPI
ISSN
2073-4409
eISSN
2073-4409
Collections
Research Team
Molecular and Systems Oncology